Abstract 112P
Background
Hepatocellular carcinoma (HCC) is a hazardous malignancy that poses a significant threat due to its asymptomatic nature and lack of an effective detection method. Individuals with chronic liver inflammation, who have a high risk of developing HCC, therefore require a sensitive detection method.
Methods
In this work, we performed a meta-analysis utilizing The Cancer Genome Atlas pan-cancer methylation database to look for promising biomarkers for HCC identification. Our findings included a methylated CpG island among many areas with distinct methylation patterns in HCC. We developed a methylation-sensitive high-resolution melting (MS-HRM) technique to detect the methylation levels of these areas in cell-free DNA (cfDNA) recovered from HCC patients. The feasibility of the assay for early-stage HCC detection was investigated.
Results
The MS-HRM approach enabled us to precisely measure the methylation levels in cell-free DNA recovered from HCC patients. Significantly, our MS-HRM test outperformed pre-existing techniques, successfully identifying 40% of patients with early-stage HCC.
Conclusions
Our results support the use of MS-HRM analysis as a viable tool for HCC monitoring. Our innovative technique has potential for improving early identification and subsequent care of this life-threatening malignancy by delivering enhanced sensitivity in identifying early-stage HCC compared to conventional assays.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Yonsei University.
Funding
Ministry of Science & ICT.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Functional characterization of the novel long intergenic non-coding RNA-RFC4, a transcript regulating chromosomal instability in prostate cancer
Presenter: Rogelio Montiel Manríquez
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - The concentration of mutated copies of driver genes in plasma closely mirrors the disease course in colorectal cancer, lung cancer, and melanoma patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Heterogeneous characteristics of KRAS mutation subtypes in surgically resected lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - ATRX-deficient IDH-wildtype adult high-grade gliomas display novel, clinically relevant genetic patterns by comprehensive genomic profiling
Presenter: Gábor Bedics
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - EGFR variant allele frequency (VAF) impacts on metastatic NSCLC patients outcome during first-line osimertinib
Presenter: Silvia Teresa Riva
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Clinical characteristics and outcomes in non-small cell lung cancer (NSCLC) with tumour and germline BRCA1/2 mutations
Presenter: Greydon Arthur
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Molecular investigation using microarray-based comparative genomic hybridization in patients with myelodysplastic syndrome and normal karyotype
Presenter: Mohamed abd naceur AMMAR
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - Unraveling methylation signatures in RAS/BRAF wild-type colorectal cancer patients to identify predictive biomarkers for anti-epidermal growth factor receptor therapy
Presenter: Ana Regina de Abreu
Session: Cocktail & Poster Display session
Resources:
Abstract
60P - Spindle cell sarcomas with tyrosine kinase rearrangement
Presenter: Lenka Krsková
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER+ breast cancer
Presenter: Ioanna Mavrommatis
Session: Cocktail & Poster Display session
Resources:
Abstract